Oilminerdeluxe wrote: THERALASE FILES PROSPECTUS FOR OFFERING OF UNITS
Toronto, Ontario – June 26, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announced today that it has filed and been receipted for a preliminary short form prospectus in connection with a marketed offering of units of the Company (the “Units”) for minimum gross proceeds of $7,500,000 and maximum gross proceeds of $15,000,000 (the “Offering”).
Each Unit will be comprised of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”). Each Warrant is expected to exercisable to acquire one Common Share at a price to be determined in the context of the market, for a period of 60 months from the initial closing date under the Offering.
The final number of Units to be distributed, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market. The Offering is being led by Mackie Research Capital Corporation as the lead agent and sole bookrunner (the “Lead Agent”), on behalf of a syndicate, including Maxim Group LLC, a United States registered broker-dealer, as sub-agent for any sales of the Units in the United States (together, the “Agents”).